Young‐Hyuck Im

1999–2025 年に発表

別表記
Young Hyuck Im · Young-Hyuck Im
93
論文数
20,983
被引用数
60
h 指数
93
i10 指数

被引用数

Young‐Hyuck Im の年別被引用数1982 年: 被引用 2 件1993 年: 被引用 3 件1999 年: 被引用 4 件2000 年: 被引用 18 件2001 年: 被引用 49 件2002 年: 被引用 34 件2003 年: 被引用 34 件2004 年: 被引用 30 件2005 年: 被引用 52 件2006 年: 被引用 36 件2007 年: 被引用 32 件2008 年: 被引用 25 件2009 年: 被引用 35 件2010 年: 被引用 37 件2011 年: 被引用 36 件2012 年: 被引用 68 件2013 年: 被引用 128 件2014 年: 被引用 124 件2015 年: 被引用 110 件2016 年: 被引用 131 件2017 年: 被引用 182 件2018 年: 被引用 170 件2019 年: 被引用 729 件2020 年: 被引用 916 件2021 年: 被引用 1,002 件2022 年: 被引用 865 件2023 年: 被引用 692 件2024 年: 被引用 993 件2025 年: 被引用 497 件2026 年: 被引用 16 件1983〜1992 年は被引用が無いため表示していません1994〜1998 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 2,322 件、この内訳の 22.2%中国: 引用元論文 992 件、この内訳の 9.5%イタリア: 引用元論文 754 件、この内訳の 7.2%イギリス: 引用元論文 555 件、この内訳の 5.3%ドイツ: 引用元論文 501 件、この内訳の 4.8%スペイン: 引用元論文 486 件、この内訳の 4.6%フランス: 引用元論文 453 件、この内訳の 4.3%韓国: 引用元論文 380 件、この内訳の 3.6%カナダ: 引用元論文 328 件、この内訳の 3.1%スイス: 引用元論文 310 件、この内訳の 3%日本: 引用元論文 309 件、この内訳の 3%ベルギー: 引用元論文 277 件、この内訳の 2.6%
0%22.2%その他 26.8%

分野

  • Medicine64.8%
  • Biochemistry, Genetics and Molecular Biology30.2%
  • Computer Science1.4%
  • Immunology and Microbiology1.3%
  • Engineering0.5%
  • Materials Science0.4%
  • その他1.4%

トピック

  • HER2/EGFR in Cancer Research10%
  • Breast Cancer Treatment Studies8.9%
  • Advanced Breast Cancer Therapies8.1%
  • PARP inhibition in cancer therapy3.6%
  • Cancer Treatment and Pharmacology3.6%
  • Cancer Genomics and Diagnostics3%
  • その他62.8%

共著者

全論文

検索で開く
  1. Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation

    著者: , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2018 被引用: 2,151

  2. Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy

    著者: , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2017 被引用: 1,887

  3. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Maria Alejandra Bartoli, Norberto Batista López, María Inés Bianconi, Laura Biganzoli, Ruemu Birhiray, Marianna Bitiņa, Ron Blachy, Kimberly Blackwell, Rita A. Blanchard, Paulette Blanchet, Ion Boiangiu, B. Bower, Christine Brezden‐Masley, Adam Brufsky, Leanne S. Budde, Priscilla B. Caguioa, Lourdes Calvo, Mario Campone, Robert R. Carroll, Hugo R. Castro, Valorie F. Chan, Veena Charu, Saverio Cinieri, Michael Clemens, Emilio Alba Conejo, Eduardo Côrtes, Bruno Coudert, Eduardo Cronemberger, Daniel de Iracema Gomes Cubero, Shaker R. Dakhil, Brooke Daniel, Neville Davidson, Maria de Fátima Dias Gauí, Susana de la Cruz, María del Pilar, G. Delgado, John Ellerton, César Estuardo, Louis Fehrenbacher, Jean-­Marc Ferrero, Patrick J. Flynn, Małgorzata Foszczyńska‐Kłoda, Sandra Franco, Hirofumi Fujii, Chris Gallagher, Teresa Gamucci, N Giacomi, Miguel Gil Gil, Antonio González-Martı́n, Vera Gorbunova, E. Gotovkin, Nathan Green, Elza Grincuka, Eva‐Maria Grischke, Vincent Hansen, Jeffrey B. Hargis, Maik Hauschild, Roberto Hegg, Carolyn B. Hendricks, Róbert Hermann, Paulo M. Hoff, Jun Horiguchi, Javier Hornedo Muguiro, Stefano Iacobelli, Kenichi Inoue, Gustavo Ismael, Yoshinori Itoh, Dr Hiroji Iwata, D Jendiroba, Rosa Jochim ほか 122 名 - The Lancet Oncology 2020 被引用: 898

  4. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

    著者: , , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2011 被引用: 2,358

  5. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2018 被引用: 1,011

  6. Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer

    著者: , , , , , , , , , , , , , - New England Journal of Medicine 2011 被引用: 2,523

  7. Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients with HR+/HER2− Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , - Clinical Cancer Research 2021 被引用: 263

  8. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial

    著者: , , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2016 被引用: 874

  9. Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial

    著者: , , , , , , , , , , , , , , , , , , , - Annals of Oncology 2020 被引用: 394

  10. Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2021 被引用: 359

  11. Multimodal deep learning models for the prediction of pathologic response to neoadjuvant chemotherapy in breast cancer

    著者: , , , , , , , - Scientific Reports 2021 被引用: 121

  12. Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2–Positive, Advanced Breast Cancer: Primary Results From the Phase III MARIANNE Study

    著者: , , , , , , , , , , , , , , - Journal of Clinical Oncology 2017 被引用: 413

  13. Phase III randomized study of taselisib or placebo with fulvestrant in estrogen receptor-positive, PIK3CA-mutant, HER2-negative, advanced breast cancer: the SANDPIPER trial

    著者: , , , , , , , , , , , , , , - Annals of Oncology 2020 被引用: 163

  14. Multi-omics profiling of younger Asian breast cancers reveals distinctive molecular signatures

    著者: , , , , , , , , , , , , , , , , , , , , , , - Nature Communications 2018 被引用: 210

  15. Prevalence and detection of low-allele-fraction variants in clinical cancer samples

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Woong‐Yang Park - Nature Communications 2017 被引用: 198

  16. Trastuzumab Emtansine Plus Pertuzumab Versus Taxane Plus Trastuzumab Plus Pertuzumab After Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2–Positive Early Breast Cancer: The Phase III KAITLIN Study

    著者: , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2021 被引用: 64

  17. Cytokine profiling in serum-derived exosomes isolated by different methods

    著者: , , , - Scientific Reports 2020 被引用: 117

  18. Trastuzumab emtansine with or without pertuzumab versus trastuzumab with taxane for human epidermal growth factor receptor 2–positive advanced breast cancer: Final results from MARIANNE

    著者: , , , , , , , , , , , , , , - Cancer 2019 被引用: 114

  19. Discordance of the PAM50 Intrinsic Subtypes Compared with Immunohistochemistry-Based Surrogate in Breast Cancer Patients: Potential Implication of Genomic Alterations of Discordance

    著者: , , , , , , , , , , , , - Cancer Research and Treatment 2018 被引用: 102

  20. Phase II DORA Study of Olaparib with or without Durvalumab as a Chemotherapy-Free Maintenance Strategy in Platinum-Pretreated Advanced Triple-Negative Breast Cancer

    著者: , , , , , , , , , , , - Clinical Cancer Research 2024 被引用: 31

  21. Deep Learning-Based Prediction Model for Breast Cancer Recurrence Using Adjuvant Breast Cancer Cohort in Tertiary Cancer Center Registry

    著者: , , , , , , , , , , , , - Frontiers in Oncology 2021 被引用: 44

  22. Impact of chemotherapy-induced alopecia distress on body image, psychosocial well-being, and depression in breast cancer patients

    著者: , , , , , , , , , , - Psycho-Oncology 2014 被引用: 225

  23. Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Sung‐Han Kim, KJ Suh, YH Park, Woong‐Yang Park, Y-L. Choi, JH Yu, Y-H Im, Ahn Js, Jy Hur, So Hyun Park, JY Kim, SJ Nam, JE Lee, SW Kim, Seung‐Koo Lee, S-A. Im, Myung‐Sun Kim, Tae‐Yop Kim, D-Y. Oh, Tae‐Yop Kim, KH Lee, DW Lee, Hyung Jun Kim, Keun‐Hwa Jung, S-B. Kim, J-H Ahn, JE Kim, JH Jung, SY Kang, MS Ahn, YW Choi, GM Kim, JH Sohn, MH Kim, SJ Koh, JK Cheon, JI Lee, ST Lim, SY Hyun, K.S. Lee, Hyung Jun Kim, M. H. Lee, JH Cho, JH Lim - The Lancet Oncology 2019 被引用: 130

  24. Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Binghe Xu, Henry Gómez, Thomas Suter, Richard D. Gelber, Edith A. Perez - Journal of Clinical Oncology 2015 被引用: 374